NCT02178215

Brief Summary

Atopic dermatitis is a chronic intermittent inflammatory skin disease. Currently, there are many cosmeceutical skin products in which their major action affects skin hydration and skin barrier function. In addition, there are some herbal medication remedies used for the treatment of skin diseases based on the knowledge of Thai traditional medicine. Patients with pruritic rash symptoms who attended the Center of Applied Thai Traditional Medicine, Siriraj Hospital, were prescribed the Holly Mangrove Shower Gel to use and on the follow-up appointment showed significant improvement. Nevertheless, the knowledge of using this herbal medication for treating pruritic skin rash so far has been categorized as folk wisdom and not been confirmed by any clinical-trial study on its efficacy and mechanism of action. Research teams chose Holly Mangrove Shower Gel containing Acanthus ebracteatus Vahl to act as adjunctive for treating atopic dermatitis. Thus, for the purpose of studying the efficacy of Holly Mangrove Shower Gel containing Acanthus ebracteatus Vahl in improving the skin barrier function in atopic dermatitis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jul 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 30, 2014

Completed
1 day until next milestone

Study Start

First participant enrolled

July 1, 2014

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
Last Updated

March 16, 2016

Status Verified

March 1, 2016

Enrollment Period

1.6 years

First QC Date

June 26, 2014

Last Update Submit

March 15, 2016

Conditions

Keywords

atopic dermatitisskin barrier functiontransepidermal water lossskin pHstratum corneum hydrationsebumwrinkle

Outcome Measures

Primary Outcomes (1)

  • Improvement of skin barrier function

    •Measurement of bioengineering property of skin using Tewameter (transepidermal water loss), Corneometer (stratum corneum hydration), pH meter (skin pH), sebumeter (sebum), and visioscan (wrinkle)

    baseline, 2 week

Secondary Outcomes (1)

  • Reduction of severity of pruritus

    baseline, 2 week

Study Arms (2)

Placebo shower gel

PLACEBO COMPARATOR

•Wash forearm by prepared placebo shower gel twice a day

Other: Placebo shower gel

Holly Mangrove Shower Gel

ACTIVE COMPARATOR

•Wash forearm by Holly Mangrove Showver gel twice a day

Other: Holly Mangrove Shower Gel

Interventions

Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks

Placebo shower gel

Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks

Holly Mangrove Shower Gel

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years old or above
  • Diagnosed as atopic dermatitis (Hanafin and Rajka criteria)
  • No active dermatitis within 2 weeks

You may not qualify if:

  • Pregnancy or lactation
  • Any other skin diseases on forearms

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Siriraj Hospital Mahidol Univeristy

Bangkok, Bangkok, 10700, Thailand

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Papapit Tuchinda, MD

    Mahidol University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2014

First Posted

June 30, 2014

Study Start

July 1, 2014

Primary Completion

February 1, 2016

Study Completion

February 1, 2016

Last Updated

March 16, 2016

Record last verified: 2016-03

Locations